Joint Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) multistakeholder workshop on Patient Registries for Alzheimer's disease

• Date:
  Monday, 15 December 2025 , 09:00 - 12:20 Amsterdam time (CET)
  Monday, 15 December 2025 , 13:10 - 17:30 Amsterdam time (CET)
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands
  Live broadcast

Event summary

This joint hybrid HMA/EMA workshop on Patient Registries follows on the successful disease-specific workshops held between 2017 and 2019, as well as the EMA multi-stakeholder workshop on qualification of Patient Registries held in 2024.

The event brings together representatives of registry holders, regulatory agencies, pharmaceutical companies, patients, healthcare professionals, academia and non-for-profit research organisations, health technology assessment bodies and payers to explore how we can work all together to foster the use of registry data for regulatory decision-making in the field of Alzheimer’s Disease.

More specifically, the main objectives of the workshop are to agree on recommendations for optimising stakeholders’ collaboration to facilitate the long-term follow-up of patients using registries, and enable the generation of meaningful evidence on the safety and effectiveness of medicines using patient registries. These objectives will be addressed by:

• Raising awareness of the evidence gaps related to current and upcoming therapies that could potentially be addressed using real-world data (RWD).
• Identifying core data elements to be collected in registries to enable the evaluation of therapies, and the effectiveness of their risk minimisation measures.
• Aligning on recommendations regarding patient consent, governance for accessing and sharing data, quality assurance and registry interoperability.

---

Note: In according with the EMA Guideline on registry-based studies, “Patient registry” (referred to as “registry” in the rest of the agenda) is defined as: Organised system that collects uniform data (clinical and other) to identify specified outcomes for a population defined by a particular disease, condition or exposure. The term ‘patient’ highlights the focus of the registry on health information. It is broadly defined and may include patients with a certain disease, pregnant or lactating women or individuals presenting with another condition such as a birth defect or a molecular or genomic feature.

Documents

Programme - Joint HMA/EMA multi-stakeholder workshop on Patient Registries December 2025

Draft

Registration

The deadline for online participation is 28 November close of business.

Please complete the following form to receive the connection details: Joint HMA/EMA Multi-stakeholder workshop on Patient Registries for Alzheimer's Disease - 15 December 2025

The registration for in-person participation is now closed. Face-to-face attendance is by invitation only.

Live broadcast - 9:00 - 17:30 (CEST)

You should see the live broadcast on pressing the 'play' icon in the video window, or a message stating that the event has not started yet.

To optimise video quality, once the video is playing we recommend clicking on the ‘Wheel’ symbol in the video window then selecting the Quality Option up to 1080p.

If the video window is blank, or if you experience other difficulties viewing the broadcast, please try connecting directly to the EMA's Vimeo Channel 1.

For technical information about the required network security settings, please see this Vimeo help page.

For further assistance, please consult the EMA Service desk.